N/A N=298 Hybrid Revascularization Observational Study
Coronary Artery Disease
Primary: Major Adverse Cardiac and Cerebrovascular Event (MACCE) — 23; 10; 3; 1 participants — p=0.80
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=35 Feasibility Study of the Magnetic Anal Sphincter (FENIX System)
Fecal Incontinence
Primary: Adverse Events — 223; 7 Number of events
Phase 4 N=30 Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
Parkinson's Disease
Primary: Modified Fatigue Impact Scale (MFIS) — 12.92; 12.69 units on a scale — p=0.81
N/A N=32 Physical Training and Heart Rate Variability in COPD
Chronic Obstructive Pulmonary Disease (COPD)
Primary: The SD1 Index, a Nonlinear Index of Heart Rate Variability (HRV)That Represents the Parassimpatetic Activity. — 3.7; 2.8; 7.1; 2.5 miliseconds
Phase 3 N=103 Home-based Exercise Via a Telecommunications System
Functional Limitation
Primary: Knee Extension Strength — 20.4; 19.5 kg
N/A N=70 Safety Study for an All-in-One Body and Personal Lubricant
Lubricating Agents
Primary: Number of Subjects With Irritation Score of "0" at Baseline and One Week — 35; 35; 35; 35 Participants
Phase 3 N=222 Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
Breast Cancer
Primary: Number of Patients With Progression-free Survival (PFS) at 24 Weeks — 67; 68 Participants
Phase 4 N=60 Efficacy of Changing to DUOTRAV® From Prior Therapy
Open-Angle Glaucoma · Ocular Hypertension · Pigment Dispersion Glaucoma
Primary: Mean Change From Baseline in IOP at Week 12 in Subjects Using Ganfort® at Baseline — 20.0; -3.8 millimeters mercury (mmHg)
Phase 2 N=24 Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
Epilepsy
Primary: Seizure Frequency — 0.655; 0.435; 0.631 Seizures per Day
Phase 2 N=10 Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
Adenocarcinoma of the Pancreas · Recurrent Pancreatic Cancer · Stage IV Pancreatic Cancer
Primary: Objective Response Rate as Measured by RECIST Criteria — 3; 6 participants
Phase 3 N=731 Prostate Cancer Intervention Versus Observation Trial (PIVOT)
Prostate Cancer
Primary: All Cause Mortality — 171; 183 Participants
Phase 3 N=109 High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Sarcoma
Primary: Number of Patients With Complete or Partial Response Assessed by RECIST Criteria — 63 percentage of participants
Phase 1 N=60 Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
Healthy
Primary: Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals From Time-Matched Analysis by Largest Time Point — 7.0; 13.0; 12.6 msec — p=<0.001
Phase 3 N=117 Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
Schizophrenia
Primary: Mean Clinical Global Impression Severity Score (CGI-S) From Baseline Through End of Study- - Safety Population. — 2.6; 1.0; 2.3; 1.1 units on a scale
Phase 3 N=2,203 Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass
Ischemic Heart Disease
Primary: Short-term End Point — 61; 77 participants